Abstract
Twenty-three patients with advanced inoperable squamous cell carcinoma of the esophagus were treated with aminothiadiazole (A-TD) 125 mg/m2 weekly plus allopurinol daily in a phase II cooperative group trial. No patients responded to treatment; 17 patients progressed, three showed stable disease, and three were unevaluable. There were no life-threatening hematologic or metabolic toxicities. The median survival from study entry was 5 months. A-TD is not active in advanced squamous cell carcinoma of the esophagus.
Publication types
-
Clinical Trial
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Adult
-
Aged
-
Aged, 80 and over
-
Allopurinol / administration & dosage
-
Antineoplastic Agents / administration & dosage*
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Carcinoma, Squamous Cell / drug therapy*
-
Carcinoma, Squamous Cell / mortality
-
Carcinoma, Squamous Cell / secondary
-
Drug Evaluation
-
Esophageal Neoplasms / drug therapy*
-
Esophageal Neoplasms / mortality
-
Female
-
Humans
-
Male
-
Middle Aged
-
Survival Rate
-
Thiadiazoles / administration & dosage*
Substances
-
Antineoplastic Agents
-
Thiadiazoles
-
Allopurinol
-
2-amino-1,3,4-thiadiazole